Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

Next Previous
Trial Profile

A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sparsentan (Primary)
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Acronyms SPARTAN

Most Recent Events

  • 11 Jun 2025 According to a Travere Therapeutics media release, company will present new biomarker data from the SPARTAN Study at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025.
  • 31 Mar 2025 According to a Travere Therapeutics media release, Company will present oral presentation from this study at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings 2025, taking place April 10-13 in Boston, MA.
  • 20 Feb 2025 According to a Travere Therapeutics media release, In 2025, the Company expects the ongoing SPARTAN Study to be expanded to include post-kidney transplant patients with recurring IgAN and has plans to initiate a new open label study of FILSPARI in post kidney-transplant patients with recurrent IgAN or FSGS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top